Lojuxta (lomitapide): Reminder to monitor the liver function of patients treated with Lojuxta and to avoid use in pregnancy

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Lojuxta
Active substance
Lomitapide
Therapeutic area (MeSH)
Hypercholesterolemia
Procedure number
EMEA/H/C/002578/S/0043
Regulatory outcome
Maintenance
DHPC type
Post-authorisation measure
Human ATC code
C10AX12
Dissemination date
17/02/2021

How useful was this page?

Add your rating